{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "School of Nursing, Shanghai Jiao Tong University School of Medicine, Shanghai, China",
    "15AstraZeneca, Translational Medicine, Oncology Randd, Waltham, USA",
    "AstraZeneca, Waltham, MA, USA",
    "Oncology Targeted Discovery, AstraZeneca, Gaithersburg, DC, USA",
    "Translational Medicine, Early Oncology & Precision Medicine, AstraZeneca, Waltham, MA, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Qing Wu"
    },
    {
      "affs": [
        1
      ],
      "name": "Flavia Michelini"
    },
    {
      "affs": [
        2
      ],
      "name": "Hung-Ying Lin"
    },
    {
      "affs": [
        3
      ],
      "name": "Isabella Tilmont"
    },
    {
      "affs": [
        4
      ],
      "name": "Lara McGrath"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5p3nbrm5qcz33.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2026-sitc2026.0482",
  "fulltext_url": null,
  "id": "5p3nbrm5qcz33",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2026-sitc2026.0482",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7225297874",
  "pdf_url": "https://jitc.bmj.com/content/14/Suppl_2/A541.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-06",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/5p3nbrm5qcz33.ris",
  "sources": [
    {
      "first_seen": "2026-11-07T14:21:08Z",
      "native_id": "18b80255740640c1bd41a76bba4a1230",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2026-sitc2026.0482"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "482 Biomarker analysis from KESTREL identifies tumor cytotoxicity and immunogenic cell death as predictors of benefit with durvalumab plus tremelimumab in HNSCC",
  "title_text": "482 Biomarker analysis from KESTREL identifies tumor cytotoxicity and immunogenic cell death as predictors of benefit with durvalumab plus tremelimumab in HNSCC",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T14:20:35Z",
  "url": "https://research.draconitic.com/paper/5p3nbrm5qcz33",
  "venue": "Journal for ImmunoTherapy of Cancer",
  "versions": []
}